Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 16/20 | 0.50 |
| ▸ | PDE4A | P27815 | 13/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644904 | 0.91 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL4642689 | 0.90 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4646587 | 0.89 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4644675 | 0.89 | PDE4A (0.54) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4646969 | 0.86 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4645365 | 0.86 | PDE4A (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4646175 | 0.86 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4644920 | 0.86 | PDE4B (0.53) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4647447 | 0.85 | PDE4B (0.50) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4644167 | 0.82 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | claimed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | claimed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.